Clinical Trial

A Phase 3 Study of HS-20094 in Patients With T2DM

Name: A Phase 3 Study of HS-20094 in Patients With T2DM — clinical trial record (NCT07156539)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The study is being conducted to evaluate the efficacy and safety of HS-20094 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Dulaglutide QW for 44 weeks and 52 weeks.

Trial Details

NCT Number	NCT07156539
Lead Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions	Type 2 Diabetes
Enrollment	546 participants
Start Date	2025-09-30
Primary Completion	2027-03-30 (estimated)
Study Completion	2027-05-30 (estimated)
Updated on ClinicalTrials.gov	2025-09-05